ImmunologybioRxivPreprint
PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSE
Elizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centeno…·Michael A. Farrar
This study compares the effects of nilotinib and dasatinib on anti-leukemia immune responses when combined with PD-L1 blockade, finding that nilotinib synergizes with PD-L1 blockade to prevent relapse while dasatinib does not.
DOI 10.1101/2025.07.02.662848